House of Lords Business
Show full summary

Lord Mendelsohn to ask Her Majesty's Government what assessment they have made of whether their strategy to protect immuno-compromised individuals is over reliant on (1) second line treatments using Sotrovimab, and (2) fourth line treatments using Molnupiravir.  HL728

Question HL728: tabled on 7 June 2022 and due for answer by 21 June 2022

This type of business sits within the Questions & Statements category.

This question has been answered by the relevant Government Department.

Question text

Lord Mendelsohn to ask Her Majesty's Government what assessment they have made of whether their strategy to protect immuno-compromised individuals is over reliant on (1) second line treatments using Sotrovimab, and (2) fourth line treatments using Molnupiravir.  HL728
Legend for business item text
† Item that is new or altered.
* Item is an oral question.
Numbers starting HL are unique identifiers for written questions, Bills or papers.

Member's Registered Interests

There are no interests to show.

Main Member

Lord Mendelsohn
Labour
Life peer